Bertoglio Sergio, Cafiero Ferdinando, Meszaros Paolo, Varaldo Emanuela, Blondeaux Eva, Molinelli Chiara, Minuto Michele
Department of Surgical Sciences (DISC), University of Genova, Genova, Italy.
General Surgery Unit 1, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
J Vasc Access. 2020 Jul;21(4):460-466. doi: 10.1177/1129729819884482. Epub 2019 Nov 1.
The increasing use of arm totally implantable vascular access devices for breast cancer patients who require chemotherapy has led to a greater risk of complications and failures and, in particular, to upper extremity deep vein thrombosis. This study aims to investigate the outcomes of the arm peripherally inserted central catheter-PORT technique in breast cancer patients.
The peripherally inserted central catheter-PORT technique is an evolution of the standard arm-totally implantable vascular access device implant based on guided ultrasound venous access in the proximal third of the upper limb with subsequent placement of the reservoir at the middle third of the arm. A prospective study was conducted on 418 adult female breast cancer patients undergoing chemotherapy. The primary study outcome was peripherally inserted central catheter-PORT failure.
Median follow-up was 215 days. Complications occurred in 29 patients (6.9%) and failure resulting in removal of the device in 11 patients (2.6%). The main complication we observed was upper extremity deep vein thrombosis, 10 (2.4%); all patients were rescued by anticoagulant treatment without peripherally inserted central catheter-PORT removal. The main reason for removal was reservoir pocket infection: 4 (0.9%) with an infection rate of 0.012 per 1000 catheter days. Cumulative 1-year risk of failure was 3.6% (95% confidence interval, 1.3%-7.1%). With regard to the patients' characteristics, body mass index <22.5 was the only significant risk for failure ( 0.027).
The peripherally inserted central catheter-PORT is a safe vascular device for chemotherapy delivery that achieves similar clinical results as traditional long-term vascular access devices (peripherally inserted central catheter and arm totally implantable vascular access device, in particular) in breast cancer patients.
对于需要化疗的乳腺癌患者,手臂完全植入式血管通路装置的使用日益增加,这导致了更高的并发症和失败风险,尤其是上肢深静脉血栓形成。本研究旨在调查乳腺癌患者中手臂外周静脉穿刺中心静脉导管-植入式输液港技术的效果。
外周静脉穿刺中心静脉导管-植入式输液港技术是基于上肢近端三分之一处超声引导静脉穿刺并随后将贮液囊置于手臂中间三分之一处的标准手臂完全植入式血管通路装置植入技术的改进。对418例接受化疗的成年女性乳腺癌患者进行了一项前瞻性研究。主要研究结局是外周静脉穿刺中心静脉导管-植入式输液港失败。
中位随访时间为215天。29例患者(6.9%)发生并发症,11例患者(2.6%)因失败导致装置移除。我们观察到的主要并发症是上肢深静脉血栓形成,共10例(2.4%);所有患者均通过抗凝治疗获救,无需移除外周静脉穿刺中心静脉导管-植入式输液港。移除的主要原因是贮液囊腔感染:4例(0.9%),感染率为每1000导管日0.012。1年累计失败风险为3.6%(95%置信区间,1.3%-7.1%)。关于患者特征,体重指数<22.5是失败的唯一显著风险因素(P=0.027)。
外周静脉穿刺中心静脉导管-植入式输液港是一种安全的化疗血管装置,在乳腺癌患者中可取得与传统长期血管通路装置(尤其是外周静脉穿刺中心静脉导管和手臂完全植入式血管通路装置)相似的临床效果。